“复旦才女”熊慧姐弟涉嫌诈骗罪被提起诉讼，睿昂基因营收净利双降

Core Viewpoint - The company, Ruian Gene, is facing significant legal challenges due to the arrest and prosecution of its actual controllers, Xiong Hui and Xiong Jun, for fraud. Despite these issues, the company asserts that its daily operations will not be adversely affected, as it has a robust governance structure and management team in place [1][2]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 242.31 million yuan, with a total profit of -28.47 million yuan and a net profit attributable to the parent company of -15.76 million yuan. The net profit, after excluding non-recurring gains and losses, was -19.25 million yuan [2][3]. - The company anticipates a revenue of 170 million to 176 million yuan for the year 2025, with expected net losses ranging from 39.91 million to 59.86 million yuan. The net profit, after excluding non-recurring items, is projected to be a loss of 49.91 million to 69.86 million yuan [2]. Operational Challenges - The company experienced a significant decline in net profit attributable to the parent company, with a year-on-year revenue decrease of approximately 66.31 million to 72.31 million yuan, representing a reduction of 27.36% to 29.84%. This decline is attributed to intensified industry competition, slower customer payments leading to credit impairment losses, and a halt in the development of its molecular diagnostic reagent center [3].